Description
Cardarine (GW501516) Research Chemical
Cardarine (GW501516, GW1516) is a PPARδ (PPAR-beta/delta) agonist developed by GlaxoSmithKline and Ligand Pharmaceuticals. Although commonly grouped with SARMs in the research chemical market, it is mechanistically distinct — it activates PPARδ rather than the androgen receptor. GW501516 development was discontinued by GSK in Phase II due to carcinogenicity signals in long-term rodent studies — this history is an important research context.
Research Applications
- Fatty acid oxidation and lipid metabolism research
- Metabolic syndrome models
- Endurance biology: PPARδ-driven gene expression changes
- Comparison with ERR agonists (SLU-PP-332) and AMPK agonists (AICAR) in exercise mimetic research
- Carcinogenicity mechanism studies
Important Research Notes
GW501516 exhibited carcinogenic effects in long-term rodent studies (doses of 5–30 mg/kg for 104 weeks). This is a critical safety consideration for in vivo research design. Consult institutional biosafety guidelines.
Product Specifications
- Purity: ≥98% HPLC confirmed
- Identity: Mass spectrometry (MW: 453.49)
- CoA: Third-party laboratory
- Form: Lyophilized powder, sealed vial
For Research Use Only (RUO). Not for human consumption.
